VRI to raise $2.9 million
Tuesday, 30 March, 2004
VRI Biomedical has announced plans to raise up to AUD$2.9 million through a just completed share placement and a non-renounceable rights issue to be put towards production and marketing of the company's proTract probiotic products.
The recent placement of nearly 5 million shares at $0.16 per share to institutional investors has raised about $743,000 after costs, while the rights issue, which is fully underwritten, is expected to raise $2.1 million.
VRI has recently launched the proTract products for symptomatic relief of gastrointestinal disorders including irritable bowel syndrome and diarrhoea in Australian pharmacies and expects 3000 pharmacies to be carrying the products by June.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
